Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693495 | 0.82 | BRD4 (0.41) | BRD4LIN28AMAP4K4FYNHSD17B2 | |
| SCHEMBL2174524 | 0.81 | TRIM24 (0.49) | HSD17B2HSD17B1ALDH1A1TRIM24TRIM33 | |
| SCHEMBL1749307 | 0.75 | MEN1 (0.42) | HPGDSBAZ2BKDM4EMITFALDH1A1 | |
| SCHEMBL28440723 | 0.75 | HSD17B1 (0.63) | MAP4K4FYNHSD17B2HSD17B1 | |
| SCHEMBL1346048 | 0.74 | KDM1A (0.56) | FYNHPGDS | |
| SCHEMBL2718039 | 0.74 | LDHA (0.52) | LDHAHPGDSBAZ2BALDH1A1 | |
| SCHEMBL30382878 | 0.74 | LDHA (0.52) | LDHAHPGDSBAZ2BALDH1A1 | |
| SCHEMBL2216638 | 0.72 | HPGDS (0.49) | HPGDS | |
| SCHEMBL13267891 | 0.71 | KDM1A (0.53) | MAP4K4FYNHPGDSALDH1A1SMN1; SMN2 | |
| SCHEMBL1400737 | 0.71 | FYN (0.41) | BRD4LIN28AMAP4K4FYNHSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7625914-B2 | Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
| EP-1943213-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | Galderma Research & Development (FR) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007049158-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-03 | — | — | WO | disclosed |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-07-06 | — | — | US | disclosed |
| EP-1638964-A1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113331-A1 | NOVEL COMPOUNDS THAT MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | BRD4 293/4885LIN28A 2779/4885MAP4K4 3045/4885 |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | BRD4 1777/4885LIN28A 4283/4885MAP4K4 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.